Me Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Me Biosciences, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include MEBIO+ and ME BIOSCIENCES. The owner is based in Boulder, CO.
3550 Frontier Ave Ste D
Boulder, CO 80301
Showing of trademarks Trademarks
Trademark Classifications
Me Biosciences, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Me Biosciences, Inc. have?
Me Biosciences, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 1 abandoned.
What trademark classes does Me Biosciences, Inc. file in?
Me Biosciences, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Me Biosciences, Inc.'s most well-known trademarks?
Me Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as MEBIO+ and ME BIOSCIENCES. These are among 2 currently registered trademarks in the portfolio.
What is Me Biosciences, Inc.'s trademark registration success rate?
Me Biosciences, Inc. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 1 application is pending review.